- Home
- SBFM vs SNOA Comparison
SBFM vs SNOA Comparison
Compare SBFM & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- SNOA
- Stock Information
- Founded
- SBFM 2006
- SNOA 1999
- Country
- SBFM United States
- SNOA United States
- Employees
- SBFM N/A
- SNOA N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- SNOA Health Care
- Exchange
- SBFM Nasdaq
- SNOA Nasdaq
- Market Cap
- SBFM 6.7M
- SNOA 6.4M
- IPO Year
- SBFM N/A
- SNOA 2007
- Fundamental
- Price
- SBFM $1.57
- SNOA $3.42
- Analyst Decision
- SBFM Strong Buy
- SNOA
- Analyst Count
- SBFM 1
- SNOA 0
- Target Price
- SBFM $15.00
- SNOA N/A
- AVG Volume (30 Days)
- SBFM 196.4K
- SNOA 94.5K
- Earning Date
- SBFM 08-15-2025
- SNOA 08-07-2025
- Dividend Yield
- SBFM N/A
- SNOA N/A
- EPS Growth
- SBFM N/A
- SNOA N/A
- EPS
- SBFM N/A
- SNOA N/A
- Revenue
- SBFM $36,234,578.00
- SNOA $14,288,000.00
- Revenue This Year
- SBFM $32.20
- SNOA $23.00
- Revenue Next Year
- SBFM $32.74
- SNOA $24.59
- P/E Ratio
- SBFM N/A
- SNOA N/A
- Revenue Growth
- SBFM 35.51
- SNOA 12.20
- 52 Week Low
- SBFM $1.17
- SNOA $1.75
- 52 Week High
- SBFM $6.19
- SNOA $8.62
- Technical
- Relative Strength Index (RSI)
- SBFM 53.18
- SNOA 51.21
- Support Level
- SBFM $1.51
- SNOA $3.41
- Resistance Level
- SBFM $1.61
- SNOA $3.79
- Average True Range (ATR)
- SBFM 0.08
- SNOA 0.31
- MACD
- SBFM 0.00
- SNOA 0.00
- Stochastic Oscillator
- SBFM 78.48
- SNOA 38.14
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.